Meeting
2017 ASCO Annual Meeting
Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.
Authors
Geoffrey John Lindeman
The Royal Melbourne Hospital, Parkville, Australia
Geoffrey John Lindeman , Sheau Wen Lok , Alice Ruth Bergin , James Richard Whittle , Kylie Shackleton , Peter Sherman , Sarah-Jane Dawson , Jayesh Desai , Danny Liew , Bruce Mann , Anand Murugasu , Andrew Warwick Roberts , Mark Rosenthal , Jane Visvader
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
ISRCTN98335443
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1044)
DOI
10.1200/JCO.2017.35.15_suppl.1044
Abstract #
1044
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA.
First Author: Geoffrey J Lindeman
Poster
2018 ASCO Annual Meeting
Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results.
First Author: Tejal Amar Patel
Poster
2014 ASCO Annual Meeting
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
First Author: Sarika Jain
Poster
2014 ASCO Annual Meeting
Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.
First Author: Tejal Amar Patel